INmune Bio's current assets is $23M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
INmune Bio (INMB) currently reports a current assets of $23M as of March 2026. That compares with $21M in the prior-year period — up 8.9% year over year. Use the charts on this page to explore INmune Bio's current assets history and peer comparisons.
INmune Bio's current assets increased from $21M to $23M — a 8.9% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
INmune Bio reported $23M in current assets as of March 2026. That compares with $21M in the prior-year period — up 8.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current current assets of $23M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for INmune Bio, and consider following INMB for alerts when major investors trade the stock.
INmune Bio is classified in the Healthcare sector. On current assets, it currently shows $23M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing INMB with unrelated industries.